% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Dietlein:893306,
author = {Dietlein, Felix and Mueller, Peter and Kobe, Carsten and
Endepols, Heike and Hohberg, Melanie and Zlatopolskiy, Boris
and Krapf, Philipp and Heidenreich, Axel and Neumaier, Bernd
and Drzezga, Alexander and Dietlein, Markus},
title = {[18{F}]-{JK}-{PSMA}-7 {PET}/{CT} {U}nder {A}ndrogen
{D}eprivation {T}herapy in {A}dvanced {P}rostate {C}ancer},
journal = {Molecular imaging and biology},
volume = {23},
number = {2},
issn = {1536-1632},
address = {Cham},
publisher = {Springer Nature Switzerland},
reportid = {FZJ-2021-02680},
pages = {277-286},
year = {2021},
abstract = {Purpose: PSMA imaging is frequently used for monitoring of
androgen deprivation therapy(ADT) in prostate cancer. In a
previous study, [18F]-JK-PSMA-7 exhibited favorable
propertiesfor tumor localization after biochemical
recurrence. In this retrospective study, we evaluated
theperformance of [18F]-JK-PSMA-7 under ADT.Procedures: We
examined the performance of [18F]-JK-PSMA-7 in 70 patients
(first cohort) withincreasing or detectable PSA values under
ADT (PSA G 2 ng/ml for 21/70 patients). We furtheranalyzed
58 independent patients with PSA levels G 2 ng/ml under ADT,
who were imaged with[68Ga]PSMA-11 or [18F]DCFPyL (second
cohort). Finally, we compared detection rates
between[18F]-JK-PSMA-7, [68Ga]PSMA-11, and
[18F]DCFPyL.Results: In the first cohort, we detected
[18F]-JK-PSMA-7-positive lesions in 63/70 patients.
Inpatients with PSA levels ≥ 2 ng/ml, the detection rate
was 100 $\%$ (49/49). In patients with PSA G 2ng/ml, the
detection rate was significantly lower (66.7 $\%,$ 14/21, p
= 9.7 × 10−5) and dropped $from85.7\%(12/14,$ PSA levels
between 0.3 and 2.0 ng/ml) to $28.6\%(2/7)$ for PSA levels G
0.3 ng/ml (p =1.73 × 10−2). In the second cohort (PSA G 2
ng/ml), the detection rate was 79.3 $\%$ (46/58)
for[68Ga]PSMA-11 or [18F]DCFPyL. Again, the detection rate
was significantly higher (p = 1.1 × 10−2)for patients
with PSA levels between 0.3 and 2.0 ng/ml (87.0 $\%,$ 40/46)
relative to those with PSAlevels G 0.3 ng/ml (50 $\%,$
6/12). No significant difference was found between
[18F]-JK-PSMA-7 and[68Ga]PSMA-11 or [18F]DCFPyL in patients
with PSA levels G 2 ng/ml (p = 0.4295).Conclusion:
[18F]-JK-PSMA-7 PET showed a high detection rate in patients
with PSA levels ≥0.3 ng/ml under ADT. The lower PSA
threshold of 0.3 ng/ml for high detection rates
wasconsistent across the three PSMA ligands. Thus, PSMA
imaging is suitable for clinical follow-upof patients with
increasing PSA levels under ADT.},
cin = {INM-5 / INM-2},
ddc = {570},
cid = {I:(DE-Juel1)INM-5-20090406 / I:(DE-Juel1)INM-2-20090406},
pnm = {525 - Decoding Brain Organization and Dysfunction
(POF4-525)},
pid = {G:(DE-HGF)POF4-525},
typ = {PUB:(DE-HGF)16},
pubmed = {33006028},
UT = {WOS:000574311700001},
doi = {10.1007/s11307-020-01546-0},
url = {https://juser.fz-juelich.de/record/893306},
}